Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Compensation Committee granted options to six employees for a total of 10,200 shares at an exercise price of $26.19, the closing price on July 25, 2022. Additionally, they received restricted stock units for 5,100 shares. These equity awards were issued under the company's 2020 Inducement Plan, approved in January 2020, compliant with NYSE Listed Company Manual Rule 303A.08. Arcus is focused on developing innovative cancer therapies, advancing six investigational medicines in clinical studies.

Arcus Biosciences, Inc. (NYSE:RCUS) has granted options to purchase 34,500 shares and restricted stock units totaling 17,250 shares to 14 new employees. The options have an exercise price of $28.78, based on the closing price on July 8, 2022. This grant is under the Company's 2020 Inducement Plan, approved by the Board in January 2020. Arcus is focused on developing innovative cancer therapies and has advanced six investigational medicines to clinical studies, targeting various biological pathways.

Arcus Biosciences (NYSE:RCUS) announced the granting of equity awards to ten new employees. The Compensation Committee approved options to purchase 22,850 shares at $24.98 per share, along with restricted stock units for 11,425 shares. This initiative is part of the Company’s 2020 Inducement Plan, which aims to attract skilled professionals in the oncology-focused biopharmaceutical sector. These awards signify the company's commitment to incentivizing talent as it continues to develop innovative cancer therapies.

Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Compensation Committee granted options for 35,050 shares and restricted stock units for 17,525 shares to 16 new employees. The exercise price is set at $23.62, reflecting the closing stock price on June 8, 2022. These grants were made under the company's 2020 Inducement Plan, approved in January 2020. The company focuses on developing innovative cancer therapies and has accelerated six investigational drugs into clinical trials since its founding in 2015.

Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022, at 9:20 a.m. PT. This event will be held at the Terranea Resort in Rancho Palos Verdes, California. A live webcast can be accessed via the Investors & Media section of the Arcus website, with a replay available post-event. Arcus is focused on developing innovative treatments for cancer, having advanced six investigational medicines into clinical studies since its founding in 2015.

Arcus Biosciences, Inc. (NYSE:RCUS) has granted stock options to fifteen new employees, allowing them to purchase 49,650 shares at an exercise price of $19.08, the closing price on May 23, 2022. Additionally, restricted stock units were awarded for 21,725 shares. These equity awards are in line with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is dedicated to developing innovative cancer therapies, emphasizing the advancement of first- or best-in-class medicines targeting various cancer-related biology and pathways.

Arcus Biosciences, Inc. (NYSE:RCUS) has granted options to purchase 31,350 shares and restricted stock units for 15,675 shares to twelve new employees. The options have an exercise price of $21.50, based on the closing price from May 9, 2022. This move is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies and has six investigational medicines in clinical studies targeting various cancer-related pathways.

Arcus Biosciences (RCUS) reported promising results from the third interim analysis of its Phase 2 ARC-7 study for domvanalimab in treating metastatic non-small cell lung cancer (NSCLC). The domvanalimab treatment arms showed significant differentiation in overall response rate (ORR) and duration of response (DoR) compared to zimberelimab alone. The company has $1.3 billion in cash, supporting ongoing Phase 3 trials. Expected updates will continue into late 2022, emphasizing their commitment to advancing innovative cancer therapies.

Arcus Biosciences (NYSE:RCUS) announced it will release its financial results and key pipeline updates for Q1 2022 on May 9, 2022, after U.S. markets close. The company focuses on developing innovative cancer treatments and has advanced six investigational medicines into clinical trials. These include combination therapies targeting TIGIT, PD-1, and the adenosine axis, among others. Founded in 2015, Arcus aims to expedite the development of medicines to improve cancer patient outcomes globally.